Pasithea Therapeutics has announced the start of a Phase I/Ib open-label trial of macrocyclic mitogen-activated protein kinase (MEK) inhibitor, PAS-004, for treating adults with neurofibromatosis type ...

During the 6‑month study, double-blind randomization to the higher concentration of NFX‑179 gel tested (1.5%) shrank cutaneous neurofibromas significantly more than did the vehicle control.

Among these tumors are cutaneous neurofibromas, benign tumors that grow from nerve terminals in the skin. Current treatment to reduce tumor growth in patients is limited to surgery, which can lead ...

NEUROFIBROMATOSIS is a congenital and hereditary disorder involving ectodermal, neuroectodermal and mesodermal tissue. Café-au-lait spots, cutaneous neurofibromas, tumors of the central and ...

Mobile images may be reliable for assessing cutaneous neurofibroma (cNF) features in patients with neurofibromatosis type 1 (NF1), according to a crowdsourced registry study that also suggests ...

The trial aims to provide insights on both plexiform and cutaneous neurofibromas and is supported by an anticipated Australian R&D Tax Incentive refund of up to 48.5% of eligible costs.

and assessing preliminary efficacy on target plexiform neurofibroma volume and cutaneous neurofibromas. Part A of the trial will enrol up to 24 subjects who will be given one of four planned PAS ...